FDA lets new Pfizer safety data onto Chantix label; Valeant offers 'olive branch' to Allergan;

@FiercePharma: Man gets 25 years for violent last-mile robberies. FiercePharmaManufacturing story | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. More from FiercePharmaManufacturing | Follow @EricPFierce

> The FDA updated labeling on Pfizer's ($PFE) Chantix to include studies that found little or no evidence of psychiatric issues in patients using it to stop smoking; the company plans to ask FDA to remove the "black box" warning now on the drug. Report

> Valeant Pharmaceuticals ($VRX) offered an "olive branch" to deal target Allergan ($AGN) via letter this week, and now says it's set to beat analyst estimates for the third quarter, answering critics of its business model. Report

> Analysts figure AbbVie ($ABBV) and Shire's ($SHPG) proposed merger will go through despite new U.S. rules on tax inversions. Report

> Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) are donating $1 million to not-for-profit groups focused on cardiovascular education; the two are partners on a blood clot-fighter, Eliquis. Report

> The U.K.'s cost-effectiveness watchdogs are eyeing a "no" vote for biologic treatments for ulcerative colitis. Report

Medical Device News

@FierceMedDev: China patent will open Asia's door to Biocept's cancer Dx tests. FierceDiagnostics story | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. More | Follow @MichaelGFierce

@VarunSaxena2: Treasury's crackdown on inversion could scupper Medtronic-Covidien deal. More | Follow @VarunSaxena2

@EmilyWFierce: Women more likely to skip prenatal testing if they have all the facts at hand, according to new study. More from NPR | Follow @EmilyWFierce

> Little is known about the Sunshine Act site ahead of launch, AdvaMed says. Article

> FDA to weigh in on cybersecurity concerns. Report

Biotech News

@FierceBiotech: Lipocine's low-T drug hits the mark in Phase III. Now it has to sway the FDA. Article | Follow @FierceBiotech

@JohnCFierce: Ahead of a split, Baxter strikes a $970M deal for Merrimack's lead cancer drug. News | Follow @JohnCFierce

@DamianFierce: But how will the $MACK deal affect the coming biotech softball playoffs? More from The Boston Globe | Follow @DamianFierce

> Waksal's back: Once-jailed biotech chief plots an IPO for his latest play. News

> Novartis-partnered Eureka rounds up $21M round for immuno-oncology drug research. Story

> Gilead heads to FDA after wrapping a PhIII HIV combo drug program. Item

> Bristol-Myers plots a 2,500-worker campus in New Jersey. Article

Drug Delivery News

> FDA moves aggressively on low-T drugs, but replacement pill still aims to enter market. Item

> Purdue team recreates tumor microenvironment to study cancer nanomed delivery. Report

> Novaliq's cyclosporin drop for dry eyes boasts PhI success. Story

> Titan Pharma trial of implant for addicts on track. Article

> English researchers fuse biologics to antibodies to treat rheumatoid arthritis. More

Diagnostics News

> NuView, Otsuka Pharmaceutical establish cancer biomarker licensing deal. News

> ImaginAb envisions in vivo molecular imaging tech as treatment assessment tool. Report

> Sequenom keeps prenatal Dx competition running with new positive data. Article

> T2 Biosystems gains FDA signoff for time-saving Candida Dx. Story

> U.K., Italy team push for regular Dx testing of prostate cancer patients under treatment. More

Pharma Marketing News

> Celgene's Otezla nabs psoriasis approval, launching next-gen showdown. Report

> J&J 'disappointed' U.K. watchdogs nixed Olysio-Sovaldi hep C combo. What next? More

> CNBC: Actavis swoops in on Allergan for Salix buyout talks. Item

> Can copay coupons be kickbacks? HHS says yes. More

> Bayer goes Glamour-ous with Girls star for new IUD campaign. Article

And Finally... A BMJ study found evidence linking the anxiety drugs benzodiazepines to Alzheimer's disease. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.